Kidney Disease

97-112 of 145

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM
Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM
Diabetes
Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM
- Frederik Persson, MD
Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF
Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF
Heart Failure
Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF
- Carlos Santos-Gallego, MD
SGLT2 inhibitor is kidney protective, even if eGFR <30
SGLT2 inhibitor is kidney protective, even if eGFR <30
Kidney Disease
SGLT2 inhibitor is kidney protective, even if eGFR <30
- Prof. George Bakris, MD
Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients
Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients
AHA 2020
Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients
- Deepak Bhatt, MD
The six pillars of therapy in HFrEF
The six pillars of therapy in HFrEF
AHA 2020
The six pillars of therapy in HFrEF
- Prof. Marc Pfeffer, MD, PhD
Incredible consistency between two SGLT2i trials in HFrEF
Incredible consistency between two SGLT2i trials in HFrEF
ESC 2020
Incredible consistency between two SGLT2i trials in HFrEF
- Milton Packer, MD
SGLT2 inhibitors: a new foundation in heart failure or another diuretic?
SGLT2 inhibitors: a new foundation in heart failure or another diuretic?
How to implement the newest heart failure therapies? - A case-based approach
SGLT2 inhibitors: a new foundation in heart failure or another diuretic?
- Prof. Rudolf de Boer
Nephroprotective effects with SGLT2i in CKD patients
Nephroprotective effects with SGLT2i in CKD patients
ESC 2020
Nephroprotective effects with SGLT2i in CKD patients
- Prof. Hiddo Heerspink, PhD
Remarkably similar findings with another SGLT2i in HFrEF
Remarkably similar findings with another SGLT2i in HFrEF
ESC 2020
Remarkably similar findings with another SGLT2i in HFrEF
- Prof. John McMurray, MD
Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?
Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?
Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 RA
Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?
- Prof. Johannes Mann, MD
Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?
Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?
Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i
Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?
- Prof. Christoph Wanner
Diabetes and CKD: is it all about managing glucose?
Diabetes and CKD: is it all about managing glucose?
Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 RA
Diabetes and CKD: is it all about managing glucose?
- Prof. Melanie Davies, MD
The cardiorenal connection and diabetes: Exploring intervention by SGLT2i
The cardiorenal connection and diabetes: Exploring intervention by SGLT2i
Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i
The cardiorenal connection and diabetes: Exploring intervention by SGLT2i
- Maria Rosa Costanzo, MD
No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i
No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i
Diabetes
No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i
- Bettina Kraus, MD
Kidney protection and SGLT2i: What do we know?
Kidney protection and SGLT2i: What do we know?
Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i
Kidney protection and SGLT2i: What do we know?
- Prof. Mark Cooper, MD
The burden of residual CV risk in the statin era
The burden of residual CV risk in the statin era
Obesity
The burden of residual CV risk in the statin era
- Erin Bohula, MD

7/9

97-112 of 145

Title

Share on ReachMD